
ZVSA Stock Forecast & Price Target
ZVSA Analyst Ratings
Bulls say
ZyVersa Therapeutics Inc. exhibits a promising outlook due to its innovative drug development platforms, particularly the Cholesterol Efflux Mediator™ VAR 200 and the monoclonal antibody inflammasome ASC inhibitor IC 100, which target chronic renal and inflammatory diseases with significant unmet medical needs. The recent $2.7 million cash influx from warrant exercises reflects strong investor interest and confidence in the company's clinical programs, with a noted increase in trading volume suggesting robust market activity. Additionally, the company has improved its probability of success for VAR 200 in treating diabetic kidney disease (DKD) to 25%, supported by strong preclinical data and the approval of a Phase 2a clinical trial protocol, indicating actionable progress in the company's therapeutic development pipeline.
Bears say
ZyVersa Therapeutics reported a significant net loss of $106.2 million for 2023, translating to a loss of $108.97 per share, which raises concerns about its financial viability. The company faces multiple risks, including potential clinical trial failures, challenges in securing regulatory approvals for its drug candidates VAR 200 and IC 100, and the possibility of limited commercial opportunities stemming from market size and competition. Additionally, issues such as insufficient funding, potential dilution from future equity financing, and the threat of delisting from Nasdaq cast further doubt on the company's outlook and operational stability.
This aggregate rating is based on analysts' research of ZyVersa Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ZVSA Analyst Forecast & Price Prediction
Start investing in ZVSA
Order type
Buy in
Order amount
Est. shares
0 shares